PARP1 and neuroblastoma: Despite preclinical studies demonstrating the efficacy of BET and PARP inhibitors individually against NB tumorigenesis, to our knowledge, this is the first study evaluating whether BET and PARP inhibition could function synergistically in combination against NB tumorigenesis.